New study aims to predict dangerous immunotherapy side effects before they happen
NCT ID NCT07192315
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will collect blood and swab samples from 160 adults with solid tumors who are about to start immunotherapy. The goal is to find a biological 'signature' that can predict which patients will develop severe immune-related side effects. If such a signature is found, it could help doctors personalize treatment and prevent serious complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a test that predicts which cancer patients are at high risk for severe immunotherapy side effects, allowing doctors to take preventive steps.
- What could go wrong
- This is an early observational study, not a treatment trial. It may not find a reliable predictive signature, and any findings will need much more testing before they can be used in routine care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID CANCERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Assistance Publique Hôpitaux de marseille
Marseille, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'Universal' cancer target outsmart resistant blood cancers?
- Can a Cancer-Fighting virus shrink resistant tumors?
- ECMO in kids with cancer: a closer look at survival and risks
- New PET tracer could sharpen cancer detection
- Double-Drug attack on Hard-to-Treat cancers
- Engineered immune cells take on Hard-to-Treat cancers